# EpiBiologics

> EpiBiologics is a San Mateo biotech building bispecific antibodies that grab disease-driving proteins on the outside of cells and drag them into the trash. Its EpiTAC platform - spun out of Jim Wells' lab at UCSF - taps a library of more than 270 internalizing receptors so degradation happens in the right tissue and nowhere else. With $280M raised across Seed, Series A and a 2026 Series B led by GV and Johnson & Johnson, the company has pushed its lead EGFR degrader, EPI-326, into a Phase 1 trial for lung and head-and-neck cancers.

- **Founded:** 2022
- **Headquarters:** San Mateo, California, United States
- **Founders:** James A. Wells (Scientific Founder (UCSF)), Josef Gramespacher (Co-Founder), Rami Hannoush (Co-Founder)
- **Team size:** ~47 employees
- **Products:** EpiTAC Platform, EPI-326, EpiAtlas
- **Notable:** Closed a $107M Series B co-led by GV and Johnson & Johnson Innovation in January 2026., Total funding raised to date: ~$280M., First patient dosed in EPI-326 global Phase 1 trial in April 2026.

## Products & services

- **EpiTAC Platform** — Modular bispecific antibody platform that pairs a target-binding arm with a degradation-inducing receptor arm, leveraging 270+ internalizing receptors for tissue-selective lysosomal degradation.
- **EPI-326** — Lead clinical candidate: a tissue-selective bispecific antibody that degrades all oncogenic mutant and wild-type forms of EGFR. In Phase 1 for NSCLC and head & neck squamous cell carcinoma.
- **EpiAtlas** — Internal map of degradation-inducing receptors used to design tissue-enriched degraders for oncology, immunology, neurodegeneration, and metabolic disease.

## Achievements

- Closed a $107M Series B co-led by GV and Johnson & Johnson Innovation in January 2026.
- Total funding raised to date: ~$280M.
- First patient dosed in EPI-326 global Phase 1 trial in April 2026.
- Platform built on peer-reviewed Wells Lab work published in Nature Biotechnology and JACS.
- Recruited senior leaders from Genentech, Altos Labs, and IGM Biosciences.

## Latest updates

- **2026-04** — First patient dosed in the global Phase 1 trial of EPI-326 for EGFR-driven solid tumors.
- **2026-01** — $107M Series B closed, co-led by GV and Johnson & Johnson Innovation.
- **2025** — Eric Humke (CMO) and Aaron Mishel (CFO) joined the executive team.
- **2024-11** — Presented disease-selective extracellular degradation data at multiple scientific meetings.
- **2023-03** — Emerged from stealth with $50M Series A co-led by Mubadala Capital and Polaris Partners.

## Links

- Website: https://epibiologics.com
- LinkedIn: https://www.linkedin.com/company/epibiologics-inc

---

Profile page: https://yespress.io/epibiologics
Published by YesPress — https://yespress.io
Last updated: 2026-06-29